scholarly journals Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment

2019 ◽  
Vol 28 (4) ◽  
pp. 503-507 ◽  
Author(s):  
Tobias Gutting ◽  
Nadine Schulte ◽  
Sebastian Belle ◽  
Johannes Betge ◽  
Nicolai Härtel ◽  
...  
Keyword(s):  
Palliative Chemotherapy ◽  
Stage Iv ◽  
Immunohistochemical Analysis ◽  
Complete Response ◽  
Metastatic Gastric Cancer ◽  
Microcytic Anemia ◽  
Poor Clinical Outcome ◽  
Multiple Liver Metastases ◽  
Trastuzumab Monotherapy

Metastatic gastric cancer (GC) and oesophagogastric junctional (OGJ) adenocarcinoma have a poor clinical outcome with a high worldwide burden of disease. A 65-year old male patient with microcytic anemia was diagnosed with stage IV OGJ adenocarcinoma with multiple liver metastases. Immunohistochemical analysis revealed a high expression of HER2 (3+). Palliative chemotherapy with FLOT (oxaliplatin, 5-fluorouracil, leucovorin and docetaxel) in combination with trastuzumab was initiated. Due to severe adverse events, the therapy was de-escalated to trastuzumab monotherapy after six months of treatment. Initial restaging revealed partial response after the combination therapy of FLOT with trastuzumab. After reduction to trastuzumab monotherapy, the disease remained stable for two years until radiological complete response was observed. Trastuzumab monotherapy was continued for another two years to maintain complete response. Eleven months after the discontinuation of the therapy, no recurrence of the disease was detected. In conclusion, complete response can be achieved under trastuzumab monotherapy in exceptional responders.

Long-term maintenance capecitabine and celecoxib improved clinical outcomes by targeting colorectal cancer micrometastasis

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 14513-14513
Author(s):  
M. Zhang ◽  
S. Curley ◽  
C. Ng ◽  
B. Kurland ◽  
S. Krishnan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Stage Iv ◽  
Complete Response ◽  
Kaplan Meier ◽  
Stage Iv Disease ◽  
Disease Site ◽  
Colorectal Cancer Patients

14513 Background: Role of mainteance therapy after achieving complete response (CR) remain undefined for patients with metasatic colorectal cancer. We studied prognostic and treatment factors including maintenance capecitabine and celecoxib (XCEL) in all 19 unresectable metastatic colorectal cancer patients (pts) who had CR from the prior XCEL study. Methods: Event charts are used to summarize the timeline of the various treatments. Kaplan-Meier survival estimates and univariate log-rank tests were used to evaluate RFS and OS as time from CR. Prognostic and treatment factors included: tumor size, metastasis number (9 solitary disease), site (13 being extrahepatic), stage on diagnosis (stage II versus III/IV), disease free interval prior to stage IV disease, surgery (5 R0, 3 R1–2 resections), lactate dehydrogenase levels, first-line irinotecan chemotherapy, radiation (9 pts ≥ 45 Gy, 3 Pts < 45 Gy), and maintenance XCEL (duration 0–50.3 months). Results: Nine of 19 patients experienced recurrence (median 13 months after CR), and 4 died during the follow-up period (median 31 months after CR). The 2-year RFS for the unresected and R1–2 resected patients was 71% versus 20% for the R0 resected patients (p = 0.07). This paradoxical RFS pattern corresponded to a RFS advantage for maintenance XCEL (p = 0.002), but not any other prognostic or treatment factors. All relapses occurred in situ following discontinuation of XCEL except for the surgical cases. Patients undergoing maintenance XCEL also benefited in OS (p = 0.04). The median OS from XCEL and from onset of metastasis reached 51.9 months (95% CI, 45 months- not reached [NR]) and 73.3 months (95% CI, NR-NR months) respectively. Conclusions: Maintenance XCEL targets colorectal micrometastases and produces a paradoxical RFS and OS advantage among the high-risk unresected/R1–2 resected patients than R0 resected patients. Prospective studies are warranted to validate roles of maintenance XCEL in the treatment of colorectal micrometastases. No significant financial relationships to disclose.

Does complete response (CR) with systemic therapy (SRx) translate into long term survival in stage IV melanoma (MM)?

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 9043-9043
Author(s):  
A. Y. Bedikian ◽  
N. E. Papadopoulos ◽  
K. B. Kim ◽  
W. Hwu ◽  
J. Homsi ◽  
...  
Keyword(s):  
Systemic Therapy ◽  
Stage Iv ◽  
Complete Response ◽  
Term Survival ◽  
Long Term Survival ◽  
Stage Iv Melanoma

Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?

2011 ◽  
Vol 21 (1) ◽  
pp. 84-90 ◽  
Author(s):  
Agop Y. Bedikian ◽  
Marcella M. Johnson ◽  
Carla L. Warneke ◽  
Nicholas E. Papadopoulos ◽  
Kevin B. Kim ◽  
...  
Keyword(s):  
Systemic Therapy ◽  
Stage Iv ◽  
Complete Response ◽  
Term Survival ◽  
Long Term Survival ◽  
Stage Iv Melanoma

scholarly journals Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy

2016 ◽  
Vol 9 (1) ◽  
pp. 106-111 ◽  
Author(s):  
Seiichiro Mitani ◽  
Shigenori Kadowaki ◽  
Hiroya Taniguchi ◽  
Hisanori Muto ◽  
Kei Muro
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Group Performance ◽  
Performance Status ◽  
Eastern Cooperative Oncology Group ◽  
Oral Intake ◽  
Complete Response ◽  
Metastatic Gastric Cancer ◽  
Response To Chemotherapy ◽  
Multiple Liver Metastases

We present the first reported case of pseudocirrhosis arising after a dramatic response to chemotherapy in metastatic gastric cancer. A 74-year-old man was diagnosed with gastric adenocarcinoma having multiple liver metastases. His general condition was poor, with an Eastern Cooperative Oncology Group performance status of 3, inadequate oral intake, and jaundice (total bilirubin 2.8 mg/dl). Chemotherapy with oxaliplatin, L-leucovorin, and 5-fluorouracil (modified FOLFOX-6) was initiated. After four treatment cycles, he experienced a marked regression of liver metastases; however, he developed massive ascites with a lobular liver surface and segmental atrophy, which were consistent with pseudocirrhosis. Chemotherapy was continued along with ascites management. Thereafter, ascites disappeared, and a complete response of the metastatic lesions was achieved at 11 months after initial treatment. He had no evidence of disease progression at 30 months after initial chemotherapy. This report suggests clinicians should recognize this entity, even in gastric cancer metastatic to the liver.

scholarly journals Factors Favoring Long Term Survival in Patients with Stage IV Epithelial Ovarian Cancer: An Institutional Research

2020 ◽  
Vol 1 (1) ◽  
pp. 15-18
Author(s):  
Hafiz Abubakar Sarwar ◽  
Jhanzeb Iftikhar ◽  
Samia Yasmeen ◽  
Fareeha Sheikh ◽  
Fatima Ali ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Induction Therapy ◽  
Performance Status ◽  
Stage Iv ◽  
Complete Response ◽  
Ca 125 ◽  
Term Survival ◽  
Long Term Survival

Objective: Our aim was to identify factors favoring long term survival in patients presenting with stage IV epithelial ovarian cancer.Methods: We did retrospective analysis of thirty patients with stage IV epithelial ovarian cancer diagnosed and treated at Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan from 2006 to 2013. Patient’s demographics, clinical data and histopathology were abstracted from cancer registry department of our hospital. Chi-square test was used to find the association between clinic-pathological variables and long term survival. Result: All patients received chemotherapy and surgery as per ovarian cancer guidelines. Of the thirty patients, eleven patients survived greater than four years median survival was recorded as thirty five months. Absence of co-morbidities and good performance status indicated good results of therapy however did not have statistically significant impact on survival. Higher CA-125 at presentation i.e.>1000(normal range : <21 U/ml), response to initial chemotherapy, interval cytoreductive surgery and complete response after induction therapy were significantly associated with long term survival (P<0.05).Conclusion: Prognosis of patients presenting with stage IV epithelial ovarian cancer remains poor. Very high values of CA-125 (>1000) at presentation, response to initial chemotherapy, interval surgical resection and complete remission after induction therapy, appear to be significant prognostic factors for long term survival. Further studies exploring molecular profiling and immunological factors are warranted.

scholarly journals Factors Favoring Long Term Survival in Patients with Stage IV Epithelial Ovarian Cancer: An Institutional Research

2020 ◽  
Vol 5 (1) ◽  
pp. 15-18
Author(s):  
Hafiz Abubakar Sarwar ◽  
Jhanzeb Iftikhar ◽  
Samia Yasmeen ◽  
Fareeha Sheikh ◽  
Fatima Ali ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Induction Therapy ◽  
Performance Status ◽  
Stage Iv ◽  
Complete Response ◽  
Ca 125 ◽  
Term Survival ◽  
Long Term Survival

Objective: Our aim was to identify factors favoring long term survival in patients presenting with stage IV epithelial ovarian cancer.Methods: We did retrospective analysis of thirty patients with stage IV epithelial ovarian cancer diagnosed and treated at Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan from 2006 to 2013. Patient’s demographics, clinical data and histopathology were abstracted from cancer registry department of our hospital. Chi-square test was used to find the association between clinic-pathological variables and long term survival. Result: All patients received chemotherapy and surgery as per ovarian cancer guidelines. Of the thirty patients, eleven patients survived greater than four years median survival was recorded as thirty five months. Absence of co-morbidities and good performance status indicated good results of therapy however did not have statistically significant impact on survival. Higher CA-125 at presentation i.e.>1000(normal range : <21 U/ml), response to initial chemotherapy, interval cytoreductive surgery and complete response after induction therapy were significantly associated with long term survival (P<0.05).Conclusion: Prognosis of patients presenting with stage IV epithelial ovarian cancer remains poor. Very high values of CA-125 (>1000) at presentation, response to initial chemotherapy, interval surgical resection and complete remission after induction therapy, appear to be significant prognostic factors for long term survival. Further studies exploring molecular profiling and immunological factors are warranted.

Multimodality treatment in stage IV squamous cell carcinoma of the head and neck. A long-term follow-up

1992 ◽  
Vol 106 (3) ◽  
pp. 234-237 ◽  
Author(s):  
A. Klima ◽  
I. Bergmann ◽  
S. Szepesi
Keyword(s):  
Head And Neck ◽  
Disease Free Survival ◽  
Stage Iv ◽  
Multimodality Treatment ◽  
Complete Response ◽  
Free Survival ◽  
Long Term Follow Up ◽  
Stage Iv Cancer

AbstractWe treated 114 patients with advanced inoperable head and neck cancer with a combined-modality protocol that included two cycles of chemotherapy followed by radiotherapy or three cycles of chemotherapy and in 18 patients with a radiosensitizing agent. At the beginning of the treatment all but one patient presented with a stage IV cancer. With a follow-up of 42–58 months, four patients are alive (three from the radiosensitizing group and one of the chemotherapy group). Complete response after the radiosensitizing agent correlated with superior prolonged disease-free survival in comparison to complete responses after chemotherapy at the level of p<0.009.

Sign in / Sign up

Export Citation Format

Share Document